^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PD-L1 (Programmed death ligand 1)

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
    1d
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=330, Recruiting, I-Mab Biopharma US Limited | N=168 --> 330 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    Opdivo (nivolumab) • Imfinzi (durvalumab) • givastomig (TJ-CD4B)
    1d
    DK222 Study at Hopkins (clinicaltrials.gov)
    P1, N=6, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PD-L1 (Programmed death ligand 1)
    1d
    An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Peking Union Medical College Hospital
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Qibeian (iparomlimab/tuvonralimab)
    1d
    STC-15-24202: STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers (clinicaltrials.gov)
    P1/2, N=188, Recruiting, STORM Therapeutics LTD | Trial completion date: Jan 2026 --> Jun 2027 | Trial primary completion date: Oct 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Loqtorzi (toripalimab-tpzi) • STC-15
    1d
    An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) (clinicaltrials.gov)
    P2, N=36, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Aug 2026
    Enrollment closed • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR wild-type • ALK wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    1d
    A Phase II Study of ILKN421H With Pembrolizumab in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, iLeukon Therapeutics, Inc.
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    1d
    Polymorphisms and overexpression of immune checkpoints PD-1, PD-L1, and CTLA-4 in DLBCL: biomarker insights from a case-control study. (PubMed, Clin Transl Oncol)
    These results suggest that overexpression of these checkpoints and related genetic variants may contribute to immune escape and disease progression in DLBCL. PD-1, PD-L1, and CTLA-4 may serve as potential biomarkers for prognosis and personalized therapy. Further large-scale studies are needed to confirm these findings.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)
    1d
    Metronomic Chemotherapy Induces Metabolic Reprogramming in Cancer Cells that Modulates Mature Regulatory Dendritic Cell Function to Stimulate Antitumor Immunity. (PubMed, Cancer Res)
    Consequently, mregDCs with reduced PD-L1 expression fostered the generation of more memory-like CD8+ T cells during their interactions. Overall, this study unveils critical biological events driving antitumor immune memory formation under therapeutic stress and provides a rationale for optimizing chemotherapy modalities.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • ATF4 (Activating Transcription Factor 4)
    |
    PD-L1 expression
    2d
    Integrating computational engines to identify TSPAN6 as a migrasome-associated target for immunotherapy sensitization. (PubMed, Front Immunol)
    Collectively, our findings establish TSPAN6 as a migrasome-related regulator driving adverse immunotherapy outcomes and responses. Targeting TSPAN6, potentially with mitoxantrone, presents a potential strategy to enhance immunotherapy efficacy.
    Journal • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TSPAN6 (Tetraspanin 6) • LGALS9 (Galectin 9) • NECTIN2 (Nectin Cell Adhesion Molecule 2)
    |
    mitoxantrone
    2d
    Chlorpromazine activates cGAS-STING signaling and reprograms the immune response in glioblastoma. (PubMed, Front Immunol)
    We demonstrate that CPZ, alone or in combination with temozolomide (TMZ), the current standard of care, activates the cGAS-STING signaling pathway, thus promoting anti-tumor immune responses. This study uncovers that CPZ exerts a previously unrecognized anti-cancer immunomodulatory activity, remodeling the immune microenvironment and enhancing the anti-tumor immune response. By overcoming TMZ resistance, CPZ not only exerts a direct anti-neoplastic effect, but also sensitizes GBM cells to standard therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    temozolomide • chlorpromazine
    2d
    Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, University of Chicago | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical
    2d
    A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment (clinicaltrials.gov)
    P2, N=68, Not yet recruiting, University of Chicago | Initiation date: Jan 2026 --> Dec 2026
    Trial initiation date • Minimal residual disease
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx • NavDx®
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)